Policy
In a Cabinet meeting, Health Secretary Robert F. Kennedy Jr. said the website could go live “probably in the next 10 days,” but an exact launch date remains unclear.
FEATURED STORIES
An inconsistent boom-and-bust cycle funding environment for early-stage biotech innovations and burdensome regulation threaten the U.S.’s half-century-long dominance in the biotech sector.
Acadia Pharma’s Catherine Owen Adams is one of the founders of a group of small- to mid-cap biotechs advocating against a ‘peanut butter blanket’ approach to drug pricing for small companies.
Former European Trade Commissioner Phil Hogan and former U.S. Senator Richard Burr, speaking on a panel at the J.P. Morgan Healthcare Conference, pushed to see a larger picture beyond the Trump administration’s year of chaos and confusion.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Late on Friday, Merck announced that it had pulled its application for Keytruda in combination with pemetrexed and carboplatin as a first-line treatment for metastatic nonsquamous NSCLC from the EMA.
Last week a federal judge asked prosecutors and the FBI to look into possible witness tampering.
Once again Insys has been rocked by an indictment.
Teva said Lilly’s planned drug would infringe five patents that cover its own migraine drug, which it sought U.S. Food and Drug Administration approval for on Oct. 16.
Incyte has been at the forefront of the IDO race with its candidate epacadostat.
The company is shuttering its GBT440 program to treat idiopathic pulmonary fibrosis (IPF).
The case was part of a consolidated trial of four women who were awarded a total of $26.7 million in compensatory damages.
The way the university handled it violated state law, according to state officials.
The company was among dozens of firms worldwide hit in the June 27 attack.
Celgene is scrapping a late-stage Crohn’s disease drug it acquired in a $710M deal three years ago following an interim data analysis.